Our portfolio of humanized mice support the development of functional cellular components of the human immune system. Mouse models with human immune cell engraftment represent ground-breaking platforms to evaluate compounds to treat a variety of human diseases.
Humanized CD34+ mice (hu-CD34) are a robust in vivo platform for analyzing the safety and effectiveness of potential new drugs to modulate the immune system. Hu-CD34+ mice are advantageous in vivo models for long-term studies in the fields of human immune cell biology, immuno-oncology, and infectious disease.
Models engrafted with cord blood-derived hematopoietic stem cells (HSC) develop multi-lineage engraftment and display robust T-cell maturation and T-cell dependent inflammatory responses. In addition, an improved human myeloid and NK lineage development is demonstrated in humanized NSG™-SGM3 and NSG™-Tg(IL15) mice. Large cohorts of humanized CD34+ NSG™, NSG™-SGM3 and NSG™-Tg(IL15) mice are available for immediate delivery or to enroll in JAX drug efficacy testing services.
|STRAIN No.||SIGNIFICANT MODELING|
|Enhanced engraftment of multiple human tissues|
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ
|Enhanced myeloid cell production|
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(IL15)1Sz/SzJ
|Enhanced Natural Killer Cell production|
Humanized PBMC (hu-PBMC) mice feature quick engraftment of adult peripheral blood mononuclear cells and enable short-term studies requiring mature human T cells. Hu-PBMC mice are used as in vivo models to study and evaluate compounds for T cell immune modulation, infectious diseases and graft rejection research. Large cohorts of humanized PBMC mice in the background of NSG or NSG MHC I/II Double Knockout are available for immediate delivery or to enroll in JAX drug efficacy testing services.
One of the primary uses of the hu-PBMC-NSG model is the study of acute graft-versus-host disease (GVHD) which is a major problem in clinical hematopoietic stem cell transplantation. NSG mice engrafted with human PBMCs develop an acute xenogeneic GVHD-like disease upon recognition of the murine cells and tissues by mature human T cells. The hu-PBMC-NSG MHC I/II Double Knockout mouse model improves upon the limited brief window available in the hu-PBMC model to conduct experiments before the PBMC engrafted mice become affected by GvHD. NSG mice deficient in murine MHC I/II when engrafted with human PBMCs show delayed development of GvHD and support long-term studies of human immunity requiring human T cell engraftment, human tumor xenograft models, and enable evaluation of immune modulators targeting human T cells.
Humanized mice contain human cell populations. Therefore, they are housed in an ABSL2 facility and are handled in a manner consistent with CDC guidelines (BMBL, 6th edition). Proper PPE and handling methods are used at all times when working with these mice.